The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary
What is this summary about? BRAF V600E-mutant metastatic colorectal cancer is difficult to treat as people often do not respond to standard of care treatment and their cancer gets worse. The BREAKWATER study looked at whether encorafenib plus cetuximab with mFOLFOX6 was a better treatment than standard of care to treat this disease. What were the results? More participants in the encorafenib plus cetuximab with mFOLFOX6 group had their tumor shrink after treatment than those in the standard of care group (61% versus 40%). Participants in the encorafenib plus cetuximab and mFOLFOX6 group might live longer after starting treatment than those in the standard of care group. The side effects reported were expected by researchers. What do the results mean? Encorafenib plus cetuximab and mFOLFOX6 is the new standard of care for this cancer.
Authors
- Cathy Eng (ORCID: https://orcid.org/0000-0003-2335-0612)
- Josep M. Tabernero (ORCID: https://orcid.org/0000-0002-2495-8139)
- Elena Beyzarov (ORCID: https://orcid.org/0000-0002-6190-9432)
- Rona Yaeger (ORCID: https://orcid.org/0000-0002-7233-5454)
- Fortunato Ciardiello (ORCID: https://orcid.org/0000-0002-4661-5540)
- Scott Kopetz
- Takayuki Yoshino (ORCID: https://orcid.org/0000-0002-0489-4756)
- Harpreet Wasan (ORCID: https://orcid.org/0000-0002-6268-2030)
- Jayesh Desai (ORCID: https://orcid.org/0000-0003-4246-9344)
- Tim Maughan (ORCID: https://orcid.org/0000-0002-0580-5065)
- Eric Van Cutsem (ORCID: https://orcid.org/0000-0002-6372-1230)
- Xiaosong Zhang (ORCID: https://orcid.org/0000-0002-0122-2356)
- Tae Won Kim (ORCID: https://orcid.org/0000-0001-9522-1997)
- Xiaoxi Zhang
- Graham Ferrier
Institutions
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Ulsan College (KR)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Liverpool (GB)
- The University of Melbourne (AU)
- Pfizer (United States) (US)
- University of Campania "Luigi Vanvitelli" (IT)
- Vanderbilt University (US)
- Peter MacCallum Cancer Centre (AU)
- Asan Medical Center (KR)
- Hammersmith Hospital (GB)
- Kettering University (US)
- University of Ulsan (KR)
- Vall d'Hebron Hospital Universitari (ES)
- National Cancer Center Hospital East (JP)
- Vanderbilt-Ingram Cancer Center
- Imperial College London (GB)
- KU Leuven (BE)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1080/14796694.2025.2491290
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00